Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study

作者：Zhi‐Cheng Jin, Bin‐Yan Zhong, Jian-Jia Chen, Hai‐Dong Zhu, Junhui Sun, Guowen Yin, Naijian Ge, Biao Luo, Wen‐Bin Ding, Wenhui Li, Li Chen, Yu-Qing Wang, Xiaoli Zhu, Wei-Zhu Yang, H. Li, Gao‐Jun Teng, for the CHANCE Investigators · 发表于：European Radiology · 年份：2023 · DOI：10.1007/s00330-023-09754-2 · 被引用次数：90 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver physiology and pathology、Cancer Immunotherapy and Biomarkers

OBJECTIVES: This study aimed to investigate the efficacy and safety of transarterial chemoembolization (TACE) plus camrelizumab, a monoclonal antibody targeting programmed death-1, and apatinib for patients with intermediate and advanced hepatocellular carcinoma (HCC) in a real-world setting. METHODS: A total of 586 HCC patients treated with either TACE plus camrelizumab and apatinib (combination group, n = 107) or TACE monotherapy (monotherapy group, n = 479) were included retrospectively. Propensity score matching analysis was used to match patients. The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety in the combination group were described in comparison to monotherapy. RESULTS: After propensity score matching (1:2), 84 patients in the combination group were matched to 147 patients in the monotherapy group. The median age was 57 years and 71/84 (84.5%) patients were male in the combination group, while the median age was 57 years with 127/147 (86.4%) male in the monotherapy group. The median OS, PFS, and ORR in the combination group were significantly higher than those in the monotherapy group (median OS, 24.1 vs. 15.7 months, p = 0.008; median PFS, 13.5 vs. 7.7 months, p = 0.003; ORR, 59.5% [50/84] vs. 37.4% [55/147], p = 0.002). On multivariable Cox regression, combination therapy was associated with significantly better OS (adjusted hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.26-0.64; p < 0.001) and PFS (adju...